These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease. Miller JL; Kupinski JM; Castella A; Ruggeri ZM J Clin Invest; 1983 Nov; 72(5):1532-42. PubMed ID: 6415113 [TBL] [Abstract][Full Text] [Related]
6. Radiation-induced nitric oxide mitigates tumor hypoxia and radioresistance in a murine SCCVII tumor model. Nagane M; Yasui H; Yamamori T; Zhao S; Kuge Y; Tamaki N; Kameya H; Nakamura H; Fujii H; Inanami O Biochem Biophys Res Commun; 2013 Aug; 437(3):420-5. PubMed ID: 23831468 [TBL] [Abstract][Full Text] [Related]
7. Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. Choi YJ; Yoon Y; Lee KY; Hien TT; Kang KW; Kim KC; Lee J; Lee MY; Lee SM; Kang DH; Lee BH FASEB J; 2014 Jul; 28(7):3197-204. PubMed ID: 24652948 [TBL] [Abstract][Full Text] [Related]
8. Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III. Houdijk WP; Sakariassen KS; Nievelstein PF; Sixma JJ J Clin Invest; 1985 Feb; 75(2):531-40. PubMed ID: 3919060 [TBL] [Abstract][Full Text] [Related]
9. Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase. Yuen CY; Wong WT; Tian XY; Wong SL; Lau CW; Yu J; Tomlinson B; Yao X; Huang Y Cardiovasc Res; 2011 Apr; 90(1):122-9. PubMed ID: 21156825 [TBL] [Abstract][Full Text] [Related]
10. Distinct abnormalities in the interaction of purified types IIA and IIB von Willebrand factor with the two platelet binding sites, glycoprotein complexes Ib-IX and IIb-IIIa. De Marco L; Mazzucato M; De Roia D; Casonato A; Federici AB; Girolami A; Ruggeri ZM J Clin Invest; 1990 Sep; 86(3):785-92. PubMed ID: 2394830 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of endothelial nitric oxide synthase activity by proline-rich tyrosine kinase 2 in response to fluid shear stress and insulin. Fisslthaler B; Loot AE; Mohamed A; Busse R; Fleming I Circ Res; 2008 Jun; 102(12):1520-8. PubMed ID: 18483407 [TBL] [Abstract][Full Text] [Related]
12. Fluvastatin inhibits regulated secretion of endothelial cell von Willebrand factor in response to diverse secretagogues. Fish RJ; Yang H; Viglino C; Schorer R; Dunoyer-Geindre S; Kruithof EK Biochem J; 2007 Aug; 405(3):597-604. PubMed ID: 17472573 [TBL] [Abstract][Full Text] [Related]
13. The effect of insulin to decrease neointimal growth after arterial injury is endothelial nitric oxide synthase-dependent. Guo J; Breen DM; Pereira TJ; Dalvi PS; Zhang H; Mori Y; Ghanim H; Tumiati L; Fantus IG; Bendeck MP; Dandona P; Rao V; Dolinsky VW; Heximer SP; Giacca A Atherosclerosis; 2015 Jul; 241(1):111-20. PubMed ID: 25974101 [TBL] [Abstract][Full Text] [Related]
14. Effect of insulin on von Willebrand factor release in normal and diabetic subjects: in vivo and in vitro studies. Kessler L; Azimzadeh A; Wiesel ML; Coumaros G; Chakfé N; Soyer C; Koehl C; Cazenave JP; Wolf P; Pinget M Horm Metab Res; 2001 Nov; 33(11):674-80. PubMed ID: 11733871 [TBL] [Abstract][Full Text] [Related]
15. Propofol protects against high glucose-induced endothelial dysfunction in human umbilical vein endothelial cells. Zhu M; Chen J; Tan Z; Wang J Anesth Analg; 2012 Feb; 114(2):303-9. PubMed ID: 22156331 [TBL] [Abstract][Full Text] [Related]
16. Relationship between plasma soluble thrombomodulin levels and insulin resistance syndrome in type 2 diabetes: a comparison with von Willebrand factor. Aso Y; Fujiwara Y; Tayama K; Takanashi K; Inukai T; Takemura Y Exp Clin Endocrinol Diabetes; 2001; 109(4):210-6. PubMed ID: 11453033 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological activation of PPAR gamma ameliorates vascular endothelial insulin resistance via a non-canonical PPAR gamma-dependent nuclear factor-kappa B trans-repression pathway. Zhang Y; Zhan RX; Chen JQ; Gao Y; Chen L; Kong Y; Zhong XJ; Liu MQ; Chu JJ; Yan GQ; Li T; He M; Huang QR Eur J Pharmacol; 2015 May; 754():41-51. PubMed ID: 25687252 [TBL] [Abstract][Full Text] [Related]
18. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. Sobel M; McNeill PM; Carlson PL; Kermode JC; Adelman B; Conroy R; Marques D J Clin Invest; 1991 May; 87(5):1787-93. PubMed ID: 2022745 [TBL] [Abstract][Full Text] [Related]
19. Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Montagnani M; Ravichandran LV; Chen H; Esposito DL; Quon MJ Mol Endocrinol; 2002 Aug; 16(8):1931-42. PubMed ID: 12145346 [TBL] [Abstract][Full Text] [Related]
20. Comparison between von Willebrand factor (VWF) and VWF antigen II in normal individuals and patients with von Willebrand disease. de Romeuf C; Mazurier C Thromb Haemost; 1998 Jul; 80(1):37-41. PubMed ID: 9684782 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]